Addex Therapeutics (GB:0QNV) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Addex Therapeutics reported a provisional net loss of CHF 1.5 million for the third quarter of 2024, affected by the prior quarter’s one-time gain from a partial business sale, while maintaining a nine-month net profit of CHF 8.3 million. The company’s cash position stands at CHF 3.3 million as of the end of September. Investors are closely watching the upcoming final results and business update scheduled for November 22, 2024.
For further insights into GB:0QNV stock, check out TipRanks’ Stock Analysis page.